Structure of the human κ-opioid receptor in complex with JDTic

Nature

Volumn 485, Issue 7398, 2012, Pages 327-332

  Wu, Huixian ^a   Wacker, Daniel ^a   Mileni, Mauro ^a   Katritch, Vsevolod ^a   Han, Gye Won ^a   Vardy, Eyal ^b   Liu, Wei ^a   Thompson, Aaron A ^a   Huang, Xi Ping ^b   Carroll, F Ivy ^c   Mascarella, S Wayne ^c   Westkaemper, Richard B ^d   Mosier, Philip D ^d   Roth, Bryan L ^b   Cherezov, Vadim ^a   Stevens, Raymond C ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c RTI INTERNATIONAL   (United States)

^d VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIMER; KAPPA OPIATE RECEPTOR; KAPPA OPIATE RECEPTOR ANTAGONIST; NALTRINDOLE; NORBINALTORPHIMINE; SALVINORIN A;

ANTAGONISM; CHEMICAL BINDING; CRYSTAL STRUCTURE; PHYSIOLOGY;

ARTICLE; BINDING AFFINITY; BINDING SITE; CRYSTAL STRUCTURE; DRUG RECEPTOR BINDING; LIGAND BINDING; PRIORITY JOURNAL; SITE DIRECTED MUTAGENESIS; STRUCTURE ACTIVITY RELATION;

BINDING SITES; CRYSTALLOGRAPHY, X-RAY; DITERPENES, CLERODANE; GUANIDINES; HUMANS; MODELS, MOLECULAR; MORPHINANS; MUTAGENESIS, SITE-DIRECTED; NALTREXONE; PIPERIDINES; PROTEIN CONFORMATION; RECEPTORS, ADRENERGIC, BETA-2; RECEPTORS, CXCR4; RECEPTORS, OPIOID, KAPPA; STRUCTURE-ACTIVITY RELATIONSHIP; TETRAHYDROISOQUINOLINES;

EID: 84862777742     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature10939     Document Type: Article

References (50)

1. Fredriksson, R., Lagerstrom, M. C., Lundin, L. G. & Schioth, H. B. The G-proteincoupled receptors in the human genome form five main families. Phylogenetic analysis, paralogon groups, and fingerprints. Mol. Pharmacol. 63, 1256-1272 (2003).
2. Waldhoer, M., Bartlett, S. E. & Whistler, J. L. Opioid receptors. Annu. Rev. Biochem. 73, 953-990 (2004).
3. Cherezov, V. et al. High-resolution crystal structure of an engineered human b2-adrenergic G protein-coupled receptor. Science 318, 1258-1265 (2007).
4. Jaakola, V. P. et al. The 2.6 angstrom crystal structure of a human A2A adenosine receptor bound to an antagonist. Science 322, 1211-1217 (2008).
5. Chien, E. Y. et al. Structure of the human dopamine D3 receptor in complex with a D2/D3 selective antagonist. Science 330, 1091-1095 (2010).
6. Warne, T. et al. Structure of a b1-adrenergic G-protein-coupled receptor. Nature 454, 486-491 (2008).
7. Shimamura, T. et al. Structure of the human histamine H1 receptor complex with doxepin. Nature 475, 65-70 (2011).
8. Wu, B. et al. Structures of the CXCR4 chemokine GPCR with small-molecule and cyclic peptide antagonists. Science 330, 1066-1071 (2010).
9. Rasmussen, S. G. et al. Crystal structure of the b2 adrenergic receptor-Gs protein complex. Nature 477, 549-555 (2011).
10. Katritch, V., Cherezov, V. & Stevens, R. C. Diversity and modularity of G proteincoupled receptor structures. Trends Pharmacol. Sci. 33, 17-27 (2011).
11. Congreve, M., Langmead, C. J., Mason, J. S. & Marshall, F. H. Progress in structure based drug design for G protein-coupled receptors. J. Med. Chem. 54, 4283-4311 (2011).
12. Kufareva, I., Rueda, M., Katritch, V., Stevens, R. C. & Abagyan, R. Status of GPCR modeling and docking as reflected by community-wide GPCR Dock 2010 assessment. Structure 19, 1108-1126 (2011).
13. Martin, W. R., Eades, C. G., Thompson, J. A., Huppler, R. E. & Gilbert, P. E. The effects of morphine-and nalorphine-like drugs in the nondependent and morphinedependent chronic spinal dog. J. Pharmacol. Exp. Ther. 197, 517-532 (1976).
14. Carlezon, W. A. Jr, Beguin, C., Knoll, A. T.&Cohen, B. M. Kappa-opioid ligands in the study and treatment of mood disorders. Pharmacol. Ther. 123, 334-343 (2009).
15. Roth, B. L. et al. Salvinorin A: a potent naturally occurring nonnitrogenous k opioid selective agonist. Proc. Natl Acad. Sci. USA 99, 11934-11939 (2002).
16. Walsh, S. L., Strain, E. C., Abreu, M. E. & Bigelow, G. E. Enadoline, a selective kappa opioid agonist: comparison with butorphanol and hydromorphone in humans. Psychopharmacology (Berl.) 157, 151-162 (2001).
17. Thomas, J. B. et al. Identification of the first trans-(3R,4R)-dimethyl- 4-(3-hydroxyphenyl)piperidine derivative to possess highly potent and selective opioid k receptor antagonist activity. J. Med. Chem. 44, 2687-2690 (2001).
18. Carroll, F. I. et al. Pharmacological properties of JDTic: a novel k-opioid receptor antagonist. Eur. J. Pharmacol. 501, 111-119 (2004).
19. Jackson, K. J., Carroll, F. I., Negus, S. S. & Damaj, M. I. Effect of the selective kappaopioid receptor antagonist JDTic on nicotine antinociception, reward, and withdrawal in the mouse. Psychopharmacology (Berl.) 210, 285-294 (2010).
20. Salom, D. et al. Crystal structure of a photoactivated deprotonated intermediate of rhodopsin. Proc. Natl Acad. Sci. USA 103, 16123-16128 (2006).
21. Mancia, F., Assur, Z.,Herman, A. G., Siegel, R.&Hendrickson, W.A. Ligandsensitivity in dimeric associations of the serotonin 5HT2c receptor. EMBO Rep. 9, 363-369 (2008).
22. Wang, J. B., Johnson, P. S., Wu, J. M., Wang, W. F. & Uhl, G. R. Human k opiate receptor second extracellular loop elevates dynorphin's affinity for human m/k chimeras. J. Biol. Chem. 269, 25966-25969 (1994).
23. Ballesteros, J. A. & Weinstein, H. Integrated methods for the construction of threedimensional models and computational probing of structure-function relations in G protein-coupled receptors. Methods Neurosci. 25, 366-428 (1995).
24. Palczewski, K. et al. Crystal structure of rhodopsin: a G protein-coupled receptor. Science 289, 739-745 (2000).
25. Xu, F. et al. Structure of an agonist-bound human A2A adenosine receptor. Science 332, 322-327 (2011).
26. Standfuss, J. et al. The structural basis of agonist-induced activation in constitutively active rhodopsin. Nature 471, 656-660 (2011).
27. Subramanian, G., Paterlini, M. G., Larson, D. L., Portoghese, P. S. & Ferguson, D. M. Conformational analysis and automated receptor docking of selective arylacetamide-based k-opioid agonists. J. Med. Chem. 41, 4777-4789 (1998).
28. Cai, T. B. et al. Synthesis and in vitro opioid receptor functional antagonism of analogues of the selective kappa opioid receptor antagonist (3R)-7-hydroxy-N-((1S)-1-{[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-pipe ridinyl]methyl}-2-methylpropyl)-1,2,3,4-tetrahydro-3-isoquinolinecarboxamide (JDTic). J. Med. Chem. 51, 1849-1860 (2008).
29. Thomas, J. B. et al. Importance of phenolic address groups in opioid kappa receptor selective antagonists. J. Med. Chem. 47, 1070-1073 (2004).
30. Runyon, S. P. et al. Analogues of (3R)-7-hydroxy-N-[(1S)-1-{[(3R,4R)-4- (3-hydroxyphenyl)-3,4-dimethyl-1-pipe ridinyl]methyl}-2-methylpropyl)-1,2,3,4- tetrahydro-3-isoquinolinecarboxamide (JDTic). Synthesis and in vitro and in vivo opioid receptor antagonist activity. J. Med. Chem. 53, 5290-5301 (2010).
31. Zimmerman, D. M., Nickander, R., Horng, J. S. & Wong, D. T. New structural concepts for narcotic antagonists defined in a 4-phenylpiperidine series. Nature 275, 332-334 (1978).
32. Vortherms, T. A., Mosier, P. D., Westkaemper, R. B. & Roth, B. L. Differential helical orientations among related G protein-coupled receptors provide a novel mechanism for selectivity. Studies with salvinorin A and the k-opioid receptor. J. Biol. Chem. 282, 3146-3156 (2007).
33. Surratt, C. K. et al.-mu opiate receptor. Charged transmembrane domain amino acids are critical for agonist recognition and intrinsic activity. J. Biol. Chem. 269, 20548-20553 (1994).
34. Befort, K. et al. The conserved aspartate residue in the third putative transmembrane domain of the delta-opioid receptor is not the anionic counterpart for cationic opiate binding but is a constituent of the receptor binding site. Mol. Pharmacol. 49, 216-223 (1996).
35. Totrov, M. & Abagyan, R. Flexible protein-ligand docking by global energy optimization in internal coordinates. Proteins 29, 215-220 (1997).
36. Metzger, T. G., Paterlini, M. G., Portoghese, P. S.&Ferguson, D. M. Application of the message-address concept to the docking of naltrexone and selective naltrexonederived opioid antagonists into opioid receptor models. Neurochem. Res. 21, 1287-1294 (1996).
37. Chen, S. et al. Mutation of a single TMVI residue, Phe282, in the b2-adrenergic receptor results in structurally distinct activated receptor conformations. Biochemistry 41, 6045-6053 (2002).
38. Chavkin, C. & Goldstein, A. Specific receptor for the opioid peptide dynorphin: structure-activity relationships. Proc. Natl Acad. Sci. USA 78, 6543-6547 (1981).
39. Yan, F. et al. Structure-based design, synthesis, and biochemical and pharmacological characterization of novel salvinorin A analogues as active state probes of the k-opioid receptor. Biochemistry 48, 6898-6908 (2009).
40. Verdonk, M. L., Cole, J. C., Hartshorn, M., Murray, C. W. & Taylor, R. Improved protein-ligand docking using GOLD. Proteins 52, 609-623 (2003).
41. Rosenbaum, D. M. et al. GPCR engineering yields high-resolution structural insights into b2-adrenergic receptor function. Science 318, 1266-1273 (2007).
42. Caffrey, M. & Cherezov, V. Crystallizing membrane proteins using lipidic mesophases. Nature Protocols 4, 706-731 (2009).
43. Cherezov, V., Peddi, A., Muthusubramaniam, L., Zheng, Y. F. & Caffrey, M. A robotic system for crystallizing membrane and soluble proteins in lipidic mesophases. Acta Crystallogr. D 60, 1795-1807 (2004).
44. Cherezov, V. et al. Rastering strategy for screening and centring of microcrystal samples of human membrane proteins with a sub-10 mm size X-ray synchrotron beam. J. R. Soc. Interface 6 (Suppl. 5), S587-S597 (2009).
45. Otwinowski, Z. & Minor, W. Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol. 276, 307-326 (1997).
46. McCoy, A. J. et al. Phaser crystallographic software. J. Appl. Cryst. 40, 658-674 (2007).
47. Murshudov, G. N., Vagin, A. A. & Dodson, E. J. Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr. D 53, 240-255 (1997).
48. Bricogne, G, et al. BUSTER v. 2.8.0 (Global Phasing, 2009).
49. Adams, P. D, et al. PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr. D 66, 213-221 (2010).
50. Emsley, P., Lohkamp, B., Scott, W. G. & Cowtan, K. Features and development of Coot. Acta Crystallogr. D 66, 486-501 (2010).